Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19
S Fioretti, CA Matson, KM Rosenberg… - Cancer Immunology …, 2023 - Springer
Abstract Anti-CD19-CAR-T cells are a successful clinical immunotherapy for B cell
lymphomas, although some lymphomas can escape attack by downregulating surface CD19 …
lymphomas, although some lymphomas can escape attack by downregulating surface CD19 …
Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19.
S Fioretti, CA Matson… - Cancer Immunology …, 2023 - search.ebscohost.com
Abstract Anti-CD19-CAR-T cells are a successful clinical immunotherapy for B cell
lymphomas, although some lymphomas can escape attack by downregulating surface CD19 …
lymphomas, although some lymphomas can escape attack by downregulating surface CD19 …
Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19
S Fioretti, CA Matson, KM Rosenberg… - Cancer Immunology …, 2023 - search.proquest.com
Abstract Anti-CD19-CAR-T cells are a successful clinical immunotherapy for B cell
lymphomas, although some lymphomas can escape attack by downregulating surface CD19 …
lymphomas, although some lymphomas can escape attack by downregulating surface CD19 …
[HTML][HTML] Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19
S Fioretti, CA Matson, KM Rosenberg… - Cancer Immunology …, 2023 - ncbi.nlm.nih.gov
Abstract Anti-CD19-CAR-T cells are a successful clinical immunotherapy for B cell
lymphomas, although some lymphomas can escape attack by downregulating surface CD19 …
lymphomas, although some lymphomas can escape attack by downregulating surface CD19 …
Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19.
S Fioretti, CA Matson, KM Rosenberg… - Cancer Immunology …, 2022 - europepmc.org
Abstract Anti-CD19-CAR-T cells have been a successful clinical immunotherapy for B cell
lymphomas although some lymphomas can escape their attack by downregulating CD19 …
lymphomas although some lymphomas can escape their attack by downregulating CD19 …
Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19
S Fioretti, CA Matson… - Cancer immunology …, 2023 - pubmed.ncbi.nlm.nih.gov
Anti-CD19-CAR-T cells are a successful clinical immunotherapy for B cell lymphomas,
although some lymphomas can escape attack by downregulating surface CD19 levels. An …
although some lymphomas can escape attack by downregulating surface CD19 levels. An …
Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19
S Fioretti, CA Matson, KM Rosenberg… - Cancer Immunology …, 2023 - experts.umn.edu
Abstract Anti-CD19-CAR-T cells are a successful clinical immunotherapy for B cell
lymphomas, although some lymphomas can escape attack by downregulating surface CD19 …
lymphomas, although some lymphomas can escape attack by downregulating surface CD19 …
[HTML][HTML] Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19
S Fioretti, CA Matson, KM Rosenberg… - Cancer immunology …, 2023 - ncbi.nlm.nih.gov
Abstract Anti-CD19-CAR-T cells have been a successful clinical immunotherapy for B cell
lymphomas although some lymphomas can escape their attack by downregulating CD19 …
lymphomas although some lymphomas can escape their attack by downregulating CD19 …